Literature DB >> 23232295

Patients with ulcerative colitis miss more days of work than the general population, even following colectomy.

Martin Neovius1, Elizabeth V Arkema, Paul Blomqvist, Anders Ekbom, Karin E Smedby.   

Abstract

BACKGROUND & AIMS: It is unclear whether colectomy restores the ability of patients with ulcerative colitis (UC) to work to precolectomy levels. We estimated the burden of sick leave and disability pension in a population-based cohort of patients with UC and the effects of colectomy.
METHODS: We performed a register-based cohort study using the Swedish National Patient Register and identified working-age patients with UC in 2005 (n = 19,714) and patients who underwent colectomies between 1998 and 2002 (n = 807). Sick leave and disability pension data were retrieved from Statistics Sweden (1995-2005). Data from each patient in the study were compared with those from 5 age-, sex-, education-, and county-matched individuals from the general population.
RESULTS: In 2005, 15% of patients with prevalent UC received a disability pension, compared with 11% of the general population, and 21% vs 13% had ≥1 sick leave episode (P < .001 for each comparison). The annual median work days lost was 0 in both groups, but patients with UC had higher mean (65 vs 45 days; difference, 20; 95% confidence interval [CI], 18-22 days) and 75th percentile work days lost (37 vs 0 days; difference, 37; 95% CI, 36-38 days). Among patients who underwent colectomies, annual days lost increased from a mean of 40 (median, 0) days 3 years before surgery to 141 (median, 99) days during the year of surgery (P < .001). The number then decreased to a mean of 85 days 3 years after surgery (median, 0). The corresponding 75th percentile days were 17, 207, and 130, respectively. Three years after colectomy, 12% did not work at all compared with 7.2% of the general population (risk difference, 5.2%; 95% CI, 2.7%-7.7%) and compared with 5.9% 3 years before colectomy (P < .001).
CONCLUSIONS: Patients with UC miss more work days than the general population in Sweden. Although most patients had no registered work loss 3 years after colectomy, work loss was not restored to presurgery or general population levels in the group that underwent colectomy during several years of follow-up.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23232295     DOI: 10.1053/j.gastro.2012.12.004

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

Review 1.  Impact of inflammatory bowel disease on disability.

Authors:  Katharina Büsch; Amnon Sonnenberg; Nick Bansback
Journal:  Curr Gastroenterol Rep       Date:  2014-10

2.  Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time--a population-based comparative study.

Authors:  I Glimelius; S Ekberg; J Linderoth; M Jerkeman; E T Chang; M Neovius; K E Smedby
Journal:  J Cancer Surviv       Date:  2015-02-18       Impact factor: 4.442

3.  Overcoming Workplace Disability in IBD Patients: An Observational Study.

Authors:  Emma Paulides; Charlotte Daker; Chris Frampton; Richard B Gearry; Tim Eglinton; Nanne K H de Boer; Charles N Bernstein; Andrew M McCombie
Journal:  Inflamm Intest Dis       Date:  2020-03-13

4.  Work and School Absenteeism in Inflammatory Bowel Disease Patients in Jeddah, Saudi Arabia: A Cross-Sectional Study.

Authors:  Mahmoud H Mosli; Abdullah A Alamri; Omar I Saadah
Journal:  Saudi J Med Med Sci       Date:  2021-04-29

5.  Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease.

Authors:  Lieke M Spekhorst; Bas Oldenburg; Ad A van Bodegraven; Dirk J de Jong; Floris Imhann; Andrea E van der Meulen-de Jong; Marieke J Pierik; Janneke C van der Woude; Gerard Dijkstra; Geert D'Haens; Mark Löwenberg; Rinse K Weersma; Eleonora A M Festen
Journal:  World J Gastroenterol       Date:  2017-12-14       Impact factor: 5.742

6.  Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn's disease.

Authors:  Chen-Ming Sun; Jie Wu; Heng Zhang; Gan Shi; Zhi-Tao Chen
Journal:  World J Gastroenterol       Date:  2017-11-28       Impact factor: 5.742

7.  5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease.

Authors:  Vipul Yadav; Yang Mai; Laura E McCoubrey; Yasufumi Wada; Motoyasu Tomioka; Satofumi Kawata; Shrikant Charde; Abdul W Basit
Journal:  Biomedicines       Date:  2021-05-20

8.  The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine.

Authors:  Aaron Yarlas; Linnette Yen; Paul Hodgkins
Journal:  Qual Life Res       Date:  2014-09-06       Impact factor: 4.147

9.  Women's Earnings are more Affected by Inflammatory Bowel Disease than Men's: A Register-Based Swedish Cohort Study.

Authors:  Åsa H Everhov; Gustaf Bruze; Jonas Söderling; Johan Askling; Jonas Halfvarson; Karin Westberg; Petter Malmborg; Caroline Nordenvall; Jonas F Ludvigsson; Ola Olén
Journal:  J Crohns Colitis       Date:  2021-06-22       Impact factor: 9.071

10.  Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.

Authors:  Isabelle Cleynen; Gabrielle Boucher; Luke Jostins; L Philip Schumm; Sebastian Zeissig; Tariq Ahmad; Vibeke Andersen; Jane M Andrews; Vito Annese; Stephan Brand; Steven R Brant; Judy H Cho; Mark J Daly; Marla Dubinsky; Richard H Duerr; Lynnette R Ferguson; Andre Franke; Richard B Gearry; Philippe Goyette; Hakon Hakonarson; Jonas Halfvarson; Johannes R Hov; Hailang Huang; Nicholas A Kennedy; Limas Kupcinskas; Ian C Lawrance; James C Lee; Jack Satsangi; Stephan Schreiber; Emilie Théâtre; Andrea E van der Meulen-de Jong; Rinse K Weersma; David C Wilson; Miles Parkes; Severine Vermeire; John D Rioux; John Mansfield; Mark S Silverberg; Graham Radford-Smith; Dermot P B McGovern; Jeffrey C Barrett; Charlie W Lees
Journal:  Lancet       Date:  2015-10-18       Impact factor: 202.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.